The Evolution of ALK+ NSCLC Care

Now Viewing

EP: 1.The Evolution of ALK+ NSCLC Care

EP: 2.Lorlatinib in Focus: Survival, Brain Metastases, and Beyond

EP: 3.Choosing Wisely: Insights from an MAIC and eXalt3

EP: 4.Applying Trial Data to Real-World Practice in ALK+ NSCLC

EP: 5.Key Differences Among ALK Inhibitors

EP: 6.Navigating ALK Inhibitor Toxicities

EP: 7.Lorlatinib’s Unique Challenges: Managing Cognitive and Metabolic AEs

EP: 8.Long-Term Success: Educating and Supporting Patients on ALK Inhibitors

EP: 9.Equitable Access to Molecular Testing and Treatment Prioritization

EP: 10.Next Steps: Post-Frontline Therapies and Resistance in ALK+ NSCLC

EP: 11.Education and Support After Progression ALK Inhibitors

EP: 12.Looking Ahead: The Next Frontier in ALK+ NSCLC Therapy

Panel Introduction

This summary is based on an AJMC Peer Exchange program titled “Advancing ALK+ NSCLC Care: Optimizing Treatment, Sequencing, and Long-Term Outcomes,” featuring the following experts:

• Ryan Haumschild, PharmD, MS, MBA, CPEL (Moderator) - vice president of Ambulatory Pharmacy at Emory Healthcare and Winship Cancer Institute of Emory University
• Elizabeth Castronovo, NP - advanced practice provider
• Martin Dietrich, MD, PhD - oncology specialist
• Mary Grizzard, MSN, FNP - family nurse practitioner
• Christine M. Lovly, MD, PhD, FASCO - oncology researcher/physician

Introduction and Treatment Landscape Evolution

• Dr Haumschild introduced the program focus on ALK+ NSCLC care optimization
• Dr Lovly posed a question regarding how the treatment landscape has evolved in recent years
• Panelists established the foundation for discussing advances in ALK-targeted therapies

Program Overview

The panelists explore strategies for optimizing care of patients with ALK-positive non–small cell lung cancer through evidence-based treatment selection, sequencing approaches, and interpretation of emerging clinical data to improve long-term outcomes.